Modafinil reduces fatigue, improves quality of life in MS: Analysis
Treatment with modafinil, a stimulant approved in the U.S. for treating certain sleep-related disorders, significantly reduced fatigue and improved overall…
Articles by Andrea Lobo, PhD
Researchers win AU$2.9M toward AI precision medicine for MS
The Australian government’s Medical Research Future Fund (MRFF) has awarded AU$2.9 million (about $1.96 million) to support a project focused…
Bit.bio launches human astrocyte product to help model brain
Bit.bio, a company that creates human-derived cell products, has launched a novel product called ioAstrocytes, which provides functional…
Subcutaneous Ocrevus approved in EU for relapsing MS, PPMS
The European Commission has approved a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) to treat adults with multiple…
Anti-CD20s effective MS therapy switch from Tysabri: Review
Switching to one of the anti-CD20 targeting therapies Ocrevus (ocrelizumab) or rituximab may be an effective strategy for…
Headaches and MS linked, and therapies may affect them: Study
A large proportion of people with multiple sclerosis (MS) experience headaches as a result of their condition, and treatment…
Helius showcases PoNS device at CMSC meeting in Nashville
Helius Medical Technologies said it has a booth at a meeting for multiple sclerosis (MS) professionals to showcase…
Progentos receives $65M to develop myelin regeneration therapies
Progentos Therapeutics said it received $65 million in funding to support the development of myelin regeneration medications able to…
Whole grain food diet may reduce risk of pediatric-onset MS: Study
A higher intake of whole grain food is significantly associated with a lower likelihood of developing pediatric-onset multiple sclerosis…
Committee favors approval of under-the-skin Ocrevus in Europe
A committee of the European Medicines Agency (EMA) is recommending the approval of a subcutaneous, or under-the-skin, formulation of…
Nektar to develop NKTR-0165 for MS, autoimmune diseases
NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by…
Foralumab found to ease fatigue in SPMS patients in access program
Fully 70% of patients with nonactive secondary progressive multiple sclerosis (SPMS) who received foralumab nasal spray in an expanded…
Kessler scientists using $700K grant to study primary fatigue in MS
A team of Kessler Foundation researchers has been granted more than $700,000 by the National Multiple Sclerosis Society for…
Enrollment full in trial of Scone device for overactive bladder
A clinical trial testing SpineX‘s Scone neuromodulation device for treating a neurogenic, or overactive, bladder, a common symptom of…
Mavenclad now OK’d in UK to also treat active relapsing MS patients
The prescribing label for Mavenclad (cladribine) in Great Britain has been extended to include the treatment of adults with…
Shorter time to 1st MS DMT found for more recent diagnoses: Study
Multiple sclerosis (MS) patients diagnosed in more recent years — specifically after 2017 — were more likely to start…
BCG vaccine to prevent tuberculosis not linked to MS risk: Study
Getting the Bacillus Calmette-Guerin (BCG) vaccine to protect against tuberculosis (TB) or having latent (inactive) TB in young adulthood aren’t…
SetPoint nerve stimulator for RRMS accepted to FDA TAP program
The U.S. Food and Drug Administration (FDA) has accepted SetPoint Medical, which is developing a nerve stimulator for people…
MSAA, Lumina partner to provide MRIs to MS patients in Ohio
Lumina Imaging has partnered with the Multiple Sclerosis Association of America (MSAA) to provide affordable brain and spinal…
Metabolon, Cardiff University partner for MS biomarker research
Metabolon and Cardiff University are partnering to discover new biomarkers that could help better understand disease mechanisms and…
Rituximab for MS may safely control disease in children, teens
Treatment with rituximab, an approved CD20 inhibitor that’s sometimes used off-label for multiple sclerosis (MS), was found to…
Phase 1 trial of KYV-101 opening in progressive MS without relapses
Researchers at Stanford University have partnered with Kyverna Therapeutics to conduct an investigator-initiated clinical trial of the company’s…
Briumvi, an infusion treatment for MS, granted 3 more patents
TG Therapeutics has secured three additional U.S. patents for Briumvi (ublituximab-xiiy), an anti-CD20 antibody that’s been approved…
Briumvi for relapsing MS now available for patients in Europe
Briumvi (ublituximab-xiiy), an approved treatment for relapsing forms of multiple sclerosis (MS), is now available to patients in…
High incidence, prevalence of pediatric-onset MS in Sweden
Sweden has a consistently high incidence and prevalence of pediatric-onset multiple sclerosis (PoMS), according to a recently published study.
Use of DMTs in pregnancy on big upswing recently: Study in France
More women with multiple sclerosis (MS) got pregnant in recent years, probably linked to a significantly higher use of…
Sudo raises $30M more to advance TYK2 inhibitor therapies to trials
Sudo Biosciences has secured an additional $30 million in funding to support the development of two TYK2 inhibitor therapies…
Sharp lymphocyte drop seen quickly in SPMS patients on Mayzent
Some people with secondary progressive multiple sclerosis (SPMS) using Mayzent (siponimod) show a severe drop in their number…
Zeposia treatment during early pregnancy may be safe in MS: Study
Treatment with Zeposia (ozanimod) during early pregnancy may be safe for women with multiple…
Gender, age at PPMS onset has no impact on disability progression
Gender and age at the onset of disease don’t seem to have a clinically relevant impact on disability…